What Is Sermorelin and What Is It Used For?

So, what is sermorelin and what is it used for? Sermorelin is a synthetic peptide made of the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29). It works as a growth hormone secretagogue, meaning it prompts the pituitary gland to release the body’s own growth hormone (GH) rather than supplying GH from outside. Historically it was used as a diagnostic tool and to treat growth failure in children; today it is most often discussed for adult wellness goals like sleep and recovery, which are off-label and not strongly evidenced. Importantly, all sermorelin available now is compounded and not FDA-approved.

What exactly is sermorelin?

Endogenous GHRH is a 44-amino-acid hormone your hypothalamus makes to tell the pituitary to release growth hormone. Sermorelin is the lab-made N-terminal fragment, the first 29 of those amino acids, which is generally regarded as the shortest fully functional fragment of GHRH that retains the full biological activity of the parent hormone. In plain terms, sermorelin is a shortened, synthetic version of one of your body’s own signaling molecules.

Because it acts on the pituitary’s GHRH receptor, sermorelin is classified as a GHRH receptor agonist. It nudges the gland to do what it already does naturally. That is the central distinction this article keeps returning to: sermorelin is not growth hormone, and it is not the same as injecting HGH.

Is sermorelin the same as HGH?

No. This is the most common point of confusion. Human growth hormone (somatropin) is the actual hormone; sermorelin is a signal that asks your pituitary to make and release more of its own GH. Because release is governed by your body’s normal feedback loops, the two are mechanistically different, and sermorelin should never be described as “HGH” or “growth hormone.”

The distinction also matters legally. In the United States it is illegal to distribute or market human growth hormone for anti-aging or other non-approved uses, with penalties defined under 21 U.S.C. 333(e). For that reason, sermorelin should not be framed as a back-door route to HGH-style “anti-aging” benefits. If you want a fuller side-by-side, see our explainer on sermorelin vs HGH.

	Sermorelin	Human growth hormone (HGH/somatropin)
What it is	Synthetic GHRH (1-29) peptide	The growth hormone itself
How it works	Signals the pituitary to release your own GH	Supplies GH directly from outside the body
FDA status today	Compounded; not FDA-approved	FDA-approved products exist for specific indications
Anti-aging marketing	Off-label, not proven	Illegal to market for anti-aging (21 U.S.C. 333(e))

Was sermorelin ever FDA-approved?

Yes, a branded version was, across two separate applications. NDA 19-863 (approved December 28, 1990) covered Geref (sermorelin acetate) as a diagnostic agent to evaluate the pituitary somatotroph’s ability to secrete growth hormone. A separate application, NDA 20-443 (approved September 26, 1997), covered Geref for the treatment of idiopathic growth hormone deficiency in children with growth failure. The Federal Register record names both NDAs and their strengths (FDA Federal Register determination).

EMD Serono notified the FDA in 2008 that Geref was being discontinued, and the FDA withdrew approval of both NDA 19-863 and NDA 20-443 effective June 18, 2009. A March 4, 2013 Federal Register notice confirmed that Geref was not withdrawn for reasons of safety or effectiveness; the discontinuation was commercial and manufacturing-related. That historical approval is for the old branded product only, and it does not carry over to today’s compounded sermorelin.

Is the sermorelin available today FDA-approved?

No. There is no FDA-approved sermorelin finished drug product currently marketed. All sermorelin available in 2026 is compounded, either by a 503A pharmacy for a specific patient or by a 503B outsourcing facility, and is therefore not FDA-approved (FDA compounding policy). The FDA has not evaluated compounded sermorelin for safety, quality, or efficacy.

Sermorelin currently sits in Category 1 of the FDA’s interim 503A bulk drug substances policy, which means the FDA does not presently intend to take enforcement action against compounders using it, pending a final determination (interim 503A policy, effective Jan 7, 2025). Category 1 status is not FDA approval and does not establish safety or efficacy. This is the same regulatory bucket that applies to several other compounded options Revive discusses, such as enclomiphene.

What is sermorelin used for today?

The original, evidence-backed uses were diagnostic testing and childhood growth-hormone deficiency. Today, with no approved product on the market, the conversation has shifted to off-label adult wellness interests: sleep quality, exercise recovery, body composition, and general “anti-aging.” These uses are not well supported by modern controlled trials, and any potential benefit varies from person to person.

A frequently cited adult study in this area is Khorram 1997, published in the Journal of Clinical Endocrinology & Metabolism. Importantly, that trial did not test sermorelin itself; it studied [Nle27]GHRH(1-29)-NH2, a closely related but distinct, norleucine-27-modified GHRH(1-29) analog, so its results are not direct evidence for sermorelin. It was a single-blind, placebo-controlled trial of just 19 healthy older adults (10 women and 9 men, ages 55-71) given 10 mcg/kg nightly for 16 weeks of active treatment. In that analog, treatment produced acute nightly GH release and a transient rise in serum IGF-1 (elevated through about 12 weeks but returning toward baseline by the 16-week endpoint), increased skin thickness in both sexes, and increased lean body mass in men only, with anabolic effects favoring men over women. That dose belongs to that study; it is not a Revive protocol, and any dosing must be set by a licensed provider. The trial is small, single-blind, nearly three decades old, and tested a modified analog rather than sermorelin, so it cannot stand in for confirmation by modern controlled research on sermorelin. For more on what people commonly expect, see our pages on sermorelin benefits and the realistic look at sermorelin before and after.

Does sermorelin work for anti-aging?

It is not a proven anti-aging therapy. The broader literature on manipulating the GH/IGF-1 axis in older adults is sobering. A systematic review of growth hormone in the healthy elderly (Liu 2007), pooling 18 RCTs and roughly 508 participants, found only small body-composition shifts, fat mass of about -2.08 kg and lean body mass of about +2.13 kg, alongside significantly more adverse events such as edema, carpal tunnel syndrome, arthralgia, and gynecomastia (DARE/NCBI abstract). Those figures are for human growth hormone, not sermorelin, and the authors concluded GH cannot be recommended as an anti-aging therapy.

An authoritative endocrinology review, Endotext’s “Growth Hormone and Aging,” reaches a similar verdict: GH reliably shifts body composition but produces inconsistent functional results, and anti-aging use is not warranted. The NEJM editorial “Can Growth Hormone Prevent Aging?” by Vance (2003) likewise warned that the public is misled by anti-aging GH marketing (NEJM, PMID 12606731). None of this proves sermorelin works for aging, and it is a strong reason to avoid “turn back the clock” framing.

One figure worth flagging because it circulates so widely: the often-quoted “117% IGF-1 increase” with cognition benefits comes from Baker 2012, a trial of tesamorelin (GHRH 1-44), a different molecule, not sermorelin (JAMA Neurology). That number and that benefit should not be attributed to sermorelin.

How is sermorelin taken, and what should you know first?

Compounded sermorelin is a prescription product that requires evaluation and a prescription from a licensed provider; it is typically given by subcutaneous injection. We do not publish dosing instructions as recommendations, because the right approach depends on your health history and provider judgment. Anyone considering it should weigh that it is compounded and not FDA-approved, and that potential side effects in the GHRH class can include injection-site reactions and joint symptoms. For deeper reading, see sermorelin side effects and sermorelin dosage.

If cost comes up, treat any figures as general US market context only, not Revive pricing; compounded peptide costs vary by formulation, dose, and pharmacy, and are provider-determined. To understand how an evaluation works, our how it works page walks through the process.

Frequently asked questions

Is sermorelin the same thing as HGH?

No. Sermorelin is a synthetic GHRH (1-29) peptide that signals your pituitary to release your own growth hormone, whereas HGH (somatropin) is the hormone itself supplied from outside. They are different molecules with different regulatory status, and sermorelin should never be called “growth hormone” or “HGH.”

Is sermorelin FDA-approved?

Not today. A branded product called Geref was once FDA-approved, first as a diagnostic agent in 1990 and then for childhood growth-hormone deficiency in 1997, but it was discontinued and both approvals were withdrawn in 2009 for commercial reasons. All sermorelin available now is compounded and not FDA-approved, and the FDA has not evaluated compounded sermorelin for safety, quality, or efficacy.

What was sermorelin originally used for?

Its FDA-approved uses were as a diagnostic agent to evaluate the pituitary’s ability to secrete growth hormone (NDA 19-863, 1990) and, under a separate application, for treating idiopathic growth hormone deficiency in children with growth failure (NDA 20-443, 1997), per the FDA’s record for Geref. Today’s off-label adult interest in sleep, recovery, and body composition is not well supported by modern controlled trials.

Does sermorelin work for anti-aging?

It is not a proven anti-aging therapy. A frequently cited adult study (Khorram 1997) was small and single-blind, and it tested a modified GHRH(1-29) analog ([Nle27]GHRH(1-29)-NH2) rather than sermorelin itself, so its results are not direct sermorelin evidence. The broader growth-hormone-in-the-elderly literature concluded growth hormone cannot be recommended for anti-aging. Individual results vary, and benefits should not be assumed.

Is the “117% IGF-1 increase” stat about sermorelin?

No. That figure comes from a 2012 trial of tesamorelin (GHRH 1-44), a different molecule published in JAMA Neurology, not sermorelin. It is incorrect to attribute that IGF-1 number or any cognition benefit to sermorelin.

How would I get sermorelin?

Compounded sermorelin requires evaluation and a prescription from a licensed provider, who decides whether it is appropriate, the formulation, and the dose. Because it is compounded and not FDA-approved, that conversation should include the limits of the current evidence and the lack of FDA evaluation for safety, quality, or efficacy.